utor, Dept. of Anatomy, K S Hegde Medical Academy, NITTE (Deemed to be University), India.
Tutor, Dept. of Anatomy, K S Hegde Medical Academy, NITTE (Deemed to be University), India.
Clin Ter. 2024 Nov-Dec;175(6):455-459. doi: 10.7417/CT.2024.5154.
BACKGROUND & OBJECTIVE: The objective of this study was to compare serum sirtuin 1 level in diabetic nephropathy patients with or without coronary artery disease. Methods: In this cross-sectional study, 108 diabetic nephropathy patients were included, among which 54 were diagnosed with coronary artery disease based on coronary angioplasty, lipid profile, drug details, and case history, while 54 were without coronary artery disease. Patients above 18 years with nephropathy, as per spot microalbuminuria test, were included. The study excluded patients with any malignancies. Ethical approval was obtained, and consent was acquired from each participant. Serum was obtained from 2ml of whole blood and stored at -20°C before measuring serum sirtuin 1 level using Enzyme Linked Immunosorbent Assay (ELISA).
The mean serum sirtuin 1 level was 2.27 ng/ml (2.033, 2.185) in diabetic nephropathy patients with coronary artery disease and 2.55 ng/ml (2.069, 2.372) in those without. Although diabetic nephropathy patients had higher serum sirtuin 1 levels, the difference was not statistically significant (p = 0.063). The ROC curve analysis yielded a cut-off value of 2.30 ng/ml, with an AUC of 0.604, indicating sirtuin 1 level may not be a robust biomarker for predicting coronary artery disease in diabetic nephropathy patients. Furthermore, no significant association was found between serum sirtuin 1 levels and microalbuminuria stages in DN patients with CAD (p = 0.705).
In conclusion, serum sirtuin 1 levels showed no significant difference between diabetic nephropathy patients with and without coronary artery disease. The analysis suggests that serum sirtuin 1 level may not strongly indicate the presence or severity of coronary artery disease in diabetic nephropathy patients.
本研究旨在比较伴有和不伴有冠状动脉疾病的糖尿病肾病患者的血清 Sirtuin 1 水平。方法：在这项横断面研究中，纳入了 108 例糖尿病肾病患者，其中 54 例患者基于冠状动脉造影、血脂谱、药物详情和病历被诊断为冠状动脉疾病，而 54 例患者则没有冠状动脉疾病。纳入依据是微量白蛋白尿检测点的年龄在 18 岁以上且患有肾病的患者。排除患有任何恶性肿瘤的患者。本研究获得了伦理批准，并获得了每位参与者的同意。采集 2ml 全血获得血清，并在 -20°C 下储存，然后使用酶联免疫吸附试验（ELISA）测量血清 Sirtuin 1 水平。结果：伴有冠状动脉疾病的糖尿病肾病患者的平均血清 Sirtuin 1 水平为 2.27ng/ml（2.033，2.185），而不伴有冠状动脉疾病的患者为 2.55ng/ml（2.069，2.372）。尽管糖尿病肾病患者的血清 Sirtuin 1 水平较高，但差异无统计学意义（p=0.063）。ROC 曲线分析得出的截断值为 2.30ng/ml，AUC 为 0.604，表明 Sirtuin 1 水平可能不是预测糖尿病肾病患者冠状动脉疾病的可靠生物标志物。此外，在伴有 CAD 的 DN 患者中，血清 Sirtuin 1 水平与微白蛋白尿阶段之间未发现显著相关性（p=0.705）。结论：总之，伴有和不伴有冠状动脉疾病的糖尿病肾病患者的血清 Sirtuin 1 水平无显著差异。分析表明，血清 Sirtuin 1 水平可能不能强烈提示糖尿病肾病患者存在或严重程度的冠状动脉疾病。
